Development of a novel and viable knock-in factor V deficiency murine model: Utility for an ultra-rare disease
PLOS One · 2025
DOI: 10.1371/journal.pone.0321864 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Juan A De Pablo-Moreno und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetic, Physiology and Microbiology, Biology School, Complutense University of Madrid, Madrid, Spain. Hauptthemen laut MEDLINE: Disease Models, Animal, Factor V Deficiency, Factor V, Gene Knock-In Techniques. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Association for Research and Cure of Factor V deficiency, Complutense University of Madrid and Banco Santander, Ministerio de Ciencia e Innovación.
Abstract (Originalsprache)
Factor V deficiency is a congenital coagulation disorder characterized by the absence or malfunction of factor V (FV). The purpose of this study was to develop a viable FV-deficient mouse model using CRISPR/Cas9 technology. A viable pathological model of the disease was not available to develop new therapies. A previous in silico study was performed to select a mutation causing a mild disease phenotype in humans (Thr1898Met missense). Such mutation was replicated in mice by CRISPR-mediated homology directed repair. Following crossing, homozygous individuals were subjected to coagulometry assays, including FV levels, prothrombin time (PT), and activated partial thromboplastin time (aPTT). The in silico study suggested that the mutation destabilizes FV structure of both mouse and human variants, putatively producing a mild phenotype of the disease in mice. Mendelian inheritance was observed in the offspring. No spontaneous signs of blood clotting disturbances, premature deaths or gestational dysfunctions were observed. FV levels in homozygous animals were 24.5% ± 5.1; 39.7 sec ± 2.8; PT was 61.8% ± 6.3; 23.4 sec ± 1.6 (INR = 1.47 ± 0.12); and aPTT was 46.9 sec ± 3.2. A viable FV-deficient mouse model was generated by introducing a missense mutation in FV. The model exhibits a mild phenotype of the disease, akin to that observed in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Genetic, Physiology and Microbiology, Biology School, Complutense University of Madrid, Madrid, Spain.
- Animal Reproduction Department, INIA, CSIC, Madrid, Spain.
- Department of Physiology, School of Veterinary Medicine, Complutense University of Madrid, Madrid, Spain.
ORCID-Profile: Juan A De Pablo-Moreno, Andrea Miguel-Batuecas, Luis Revuelta, Antonio Liras
Förderung
- Association for Research and Cure of Factor V deficiency
- Complutense University of Madrid and Banco Santander
- Ministerio de Ciencia e Innovación
- Comunidad de Madrid
Zitieren
APA
De Pablo-Moreno, J. A., González-Brusi, L., Miguel-Batuecas, A., Bermejo-Álvarez, P., Revuelta, L., & Liras, A. (2025). Development of a novel and viable knock-in factor V deficiency murine model: Utility for an ultra-rare disease. PLOS One. https://doi.org/10.1371/journal.pone.0321864
Vancouver
De Pablo-Moreno JA, González-Brusi L, Miguel-Batuecas A, Bermejo-Álvarez P, Revuelta L, Liras A. Development of a novel and viable knock-in factor V deficiency murine model: Utility for an ultra-rare disease. PLOS One. 2025. doi:10.1371/journal.pone.0321864
BibTeX
@article{DePabloMoreno2025,
author = {De Pablo-Moreno, Juan A and González-Brusi, Leopoldo and Miguel-Batuecas, Andrea and Bermejo-Álvarez, Pablo and Revuelta, Luis and Liras, Antonio},
title = {Development of a novel and viable knock-in factor V deficiency murine model: Utility for an ultra-rare disease},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0321864}
}
EUVIMED